CuraVac will attend BIO-Europe 2026
From 9 to 11 November 2026, CuraVac will be in Cologne, Germany, to meet with investors and other pharmaceutical companies in order to develop investment, collaboration, and licensing partnerships. We are happy to collaborate with actors from all around the world toward the commercialization of our veterinary treatment and the next stage of human clinical trials for Myasthenia Gravis.
This year, Koelnmesse welcomes biotech’s yearly mass. BIO-Europe, one of the leading partnering conferences for the global biotechnology and biopharma industries, will take place from 9 November to 11 November in Cologne, Germany. CuraVac is pleased to announce it will be present and is looking to build relationships in preparation for the exciting next steps of both its human and veterinary programs.
CuraVac wishes to meet with investors, pharmaceutical companies, and other potential partners interested in licensing partnerships, collaboration or investment deals. CuraVac’s team is excited to share the opportunity of bringing its veterinary treatment for Myasthenia Gravis, CV-MG01, to market (scheduled for 2028) all around the globe and to advance toward Phase 2 clinical trials with humans.
The event is an opportunity to explore synergies across the global pharmaceutical industry to best address autoimmune diseases and rare diseases such as Myasthenia Gravis, and to exchange around disruptive innovation, that Targeted Active Therapies are an excellent example of.
Wish to book a meeting with CuraVac? Send us a request on BIO-Europe’s dedicated platform, partneringONE.
Restons en contact
Une question, ou l'envie de nous soutenir ?